Increasing number of anti-HIV drugs but no definite cure: Review of anti-HIV drugs

Pharmacy World and Science

Volumn 26, Issue 3, 2004, Pages 133-136

  Stolk, Leo M L ^a   Lüers, Jos F J ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Hanzeplein 1   (Netherlands)

Author keywords

AIDS; Anti HIV drugs; Anti retroviral; Fusion inhibitors; HIV; Non nucleoside reverse trancriptase inhibitors; Nucleoside reverse trancriptase inhibitors; Protease inhibitors

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

CARDIOVASCULAR RISK; CROSS RESISTANCE; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; EMBASE; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; MACROCYTIC ANEMIA; MALAISE; MEDLINE; METABOLIC DISORDER; MOUTH ULCER; MYOPATHY; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHOSPHORYLATION; REVIEW; SIDE EFFECT; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PATIENT COMPLIANCE; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 3542991447     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAR.0000026815.44214.83     Document Type: Review

References (9)

1. Borleff JCC, Danner SA, Lange JMA, van Everdingen JJE. CBO richtlijn antiretrovirale behandeling in Nederland. [CBO guidelines: anti-retroviral treatment in the Netherlands.] Ned Tijdschr Geneesk 2001; 136: 1585-9.
2. Gallant JE. Initial therapy of HIV infections. J Clin Virol 2002; 25: 317-33.
3. Chapman T, McGavin J, Noble S. Tenofovir disoproxil fumarate. Drugs 2003; 63: 1597-608.
4. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J Antimicrob Chem 2003; 51: 213-17.
5. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beynen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42: 223-83
6. Hansten PD, Horn JR. Hansten and Horn's interactions analysis and management. Edmonds, Washington: H&H Publications, 1999.
7. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35: 1219-30.
8. Deeks SG, Wrin T, Lieger T, Hoh R, Hayden M, Helmm NS et al. Virological and immunological consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-80.
9. Aarnoutse RE, Schapiro JM, Boucher CAB, Hekster YA, Burger DM. Therapeutic drug monitoring an aid to optimizing response to antiretroviral drugs? Drugs 2003; 63: 741-53.